Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Study of Androgen Receptor Inhibition With dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm

NCT05059236 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05059236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05059236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Study of Androgen Receptor Inhibition With dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
November 4, 2021
Completion date
June 15, 2026
Enrollment
223 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer